Judge Rules Collegium Pharmaceutical Inc. Does Not Infringe Two OxyContin Patents

October 1, 2018

A Massachusetts federal judge recently ruled that Robins Kaplan client Collegium Pharmaceutical Inc. did not infringe upon two of Purdue Pharma LP’s OxyContin-related patents. The ruling represents a significant victory for Collegium and its two-year-old drug, Xtampza XR.

Law360 covered the ruling in a recent article:
Xtampza Not Infringing 2 OxyContin Patents, Judge Says

All Content © 2018, Portfolio Media, Inc.

Related Publications

September 22, 2020
Herbal Patent Protection
Shui Li - 闻宁阁 American Intellectual Property
August 26, 2020
INSIGHT: Avoiding Trade Secret Claims After Seeing a Competitor’s Crown Jewels
Jake Holdreith, David Prange, Emily Tremblay - Bloomberg Law
July 2020
Hatch-Waxman Patent Litigation Strategies
Jeffrey Alan Hovden - LexisNexis
June 2020
Trade Secrets: Safe as Houses
Christopher Larus, David Prange, Alyssa Bixby-Lawson - Intellectual Property Magazine
Back to Top